Chronic Kidney Disease and Its Complications

Primary Care - Clinics in Office Practice

Volumn 35, Issue 2, 2008, Pages 329-344

  Thomas, Robert ^a   Kanso, Abbas ^a   Sedor, John R ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; C REACTIVE PROTEIN; DEXTRAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; RECOMBINANT ERYTHROPOIETIN; SIMVASTATIN; VITAMIN D;

ANEMIA; ANGINA PECTORIS; ARTERIAL STIFFNESS; BLOOD PRESSURE MONITORING; BLOOD TRANSFUSION; BLOOD VESSEL CALCIFICATION; BONE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; ENTERIC FEEDING; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; METABOLIC DISORDER; MINERAL METABOLISM; NUTRITIONAL ASSESSMENT; OSTEODYSTROPHY; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ANEMIA; BONE DISEASES; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; KIDNEY FAILURE, CHRONIC; METABOLIC DISEASES; RISK FACTORS;

EID: 43549084136     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2008.01.008     Document Type: Review

References (61)

1. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 298 (2007) 2038-2047
2. Levin A. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47 (2006) S11-S15
3. Levey A.S., Eckardt K.U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 67 (2005) 2089-2100
4. Coresh J., Astor B.C., Greene T., et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 41 (2003) 1-12
5. Hsu C.Y., Vittinghoff E., Lin F., et al. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 141 (2004) 95-101
6. World Health Organization. Nutritional anaemias: Report of a WHO scientific group. 1968.
7. Besarab A., and Levin A. Defining a renal anemia management period. Am J Kidney Dis 36 (2000) S13-S23
8. McClellan W., Aronoff S.L., Bolton W.K., et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 20 (2004) 1501-1510
9. Ratcliffe P.J. Molecular biology of erythropoietin. Kidney Int 44 (1993) 887-904
10. Levin A., Singer J., Thompson C.R., et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 27 (1996) 347-354
11. Muzzarelli S., and Pfisterer M. Anemia as independent predictor of major events in elderly patients with chronic angina. Am Heart J 152 (2006) 991-996
12. Fink J., Blahut S., Reddy M., et al. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 37 (2001) 348-355
13. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
14. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
15. Silverberg D. Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant 18 Suppl 2 (2003) ii7-ii12
16. Dowling T.C. Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview. Am J Health Syst Pharm 64 (2007) S3-S7
17. Moe S., Drueke T., Cunningham J., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69 (2006) 1945-1953
18. Gal-Moscovici A., and Sprague S.M. Bone health in chronic kidney disease-mineral and bone disease. Adv Chronic Kidney Dis 14 (2007) 27-36
19. Joy M.S., Karagiannis P.C., and Peyerl F.W. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm 13 (2007) 397-411
20. Hruska K.A., and Teitelbaum S.L. Renal osteodystrophy. N Engl J Med 333 (1995) 166-174
21. Llach F. Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited. Am J Kidney Dis 25 (1995) 663-679
22. Lee G.H., Benner D., Regidor D.L., et al. Impact of kidney bone disease and its management on survival of patients on dialysis. J Ren Nutr 17 (2007) 38-44
23. El-Kishawi A.M., and El-Nahas A.M. Renal osteodystrophy: review of the disease and its treatment. Saudi J Kidney Dis Transpl 17 (2006) 373-382
24. Hutchison J.A. Vascular calcification in dialysis patients. Prilozi 28 (2007) 215-224
25. Moe S.M. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 36 Suppl 2 (2006) 51-62
26. Noordzij M., Korevaar J.C., Boeschoten E.W., et al. The Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline for bone metabolism and disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 46 (2005) 925-932
27. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 (1998) S112-S119
28. Muntner P., He J., Astor B.C., et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 16 (2005) 529-538
29. Port F.K., Hulbert-Shearon T.E., Wolfe R.A., et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 33 (1999) 507-517
30. Tonelli M., Keech A., Shepherd J., et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 16 (2005) 3748-3754
31. Combe C., McCullough K.P., Asano Y., et al. Kidney Disease Outcomes Quality Initiative (K/DOQI) and the Dialysis Outcomes and Practice Patterns Study (DOPPS): nutrition guidelines, indicators, and practices. Am J Kidney Dis 44 (2004) S39-S46
32. Block G.A., Hulbert-Shearon T.E., Levin N.W., et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31 (1998) 607-617
33. Goodman W.G., London G., Amann K., et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 43 (2004) 572-579
34. Kestenbaum B., Sampson J.N., Rudser K.D., et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16 (2005) 520-528
35. Kramer H., Toto R., Peshock R., et al. Association between chronic kidney disease and coronary artery calcification: The Dallas Heart Study. J Am Soc Nephrol 16 (2005) 507-513
36. Tomiyama C., Higa A., Dalboni M.A., et al. The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Nephrol Dial Transplant 21 (2006) 2464-2471
37. Menon V., and Sarnak M.J. The epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease: a high-risk combination. Am J Kidney Dis 45 (2005) 223-232
38. Hoehner C.M., Greenlund K.J., Rith-Najarian S., et al. Association of the insulin resistance syndrome and microalbuminuria among nondiabetic Native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol 13 6 (2002) 1626-1634
39. Wachtell K., Olsen M.H., Dahlof B., et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. J Hypertens 20 (2002) 405-412
40. Gerstein H.C., Mann J.F.E., Yi Q.L., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286 (2001) 421-426
41. Bibbins-Domingo K., Chertow G.M., Fried L.F., et al. Renal function and heart failure risk in older black and white individuals-the health, aging, and body composition study. Arch Intern Med 166 (2006) 1396-1402
42. Smith G.L., Lichtman J.H., Bracken M.B., et al. Renal impairment and outcomes in heart failure-systematic review and meta-analysis. J Am Coll Cardiol 47 (2006) 1987-1996
43. Kasiske B.L. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 32 (1998) S142-S156
44. Yamauchi A., Fukuhara Y., Yamamoto S., et al. Oncotic pressure regulates gene transcriptions of albumin and apolipoprotein-B in cultured rat hepatoma-cells. Am J Phys 263 (1992) C397-C404
45. Arnadottir M., and NilssonEhle P. Has parathyroid hormone any influence on lipid metabolism in chronic renal failure?. Nephrol Dial Transplant 10 (1995) 2381-2382
46. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
47. Iseki K., Yamazato M., Tozawa M., et al. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 61 (2002) 1887-1893
48. Eknoyan G., Levin A., and Levin N. K/DOQ1 clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 41 (2003) S6-S91
49. Cleeman J.I., Grundy S.M., Becker D., et al. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
50. Appel G.B., Blum C.B., Chien S., et al. The hyperlipidemia of the nephrotic syndrome-relation to plasma-albumin concentration, oncotic pressure, and viscosity. N Engl J Med 312 (1985) 1544-1548
51. Khan I.H., Catto G.R.D., Edward N., et al. Death during the first 90 days of dialysis-a case-control study. Am J Kidney Dis 25 (1995) 276-280
52. Herrmann F.R., Safran C., Levkoff S.E., et al. Serum-albumin level on admission as a predictor of death, length of stay, and readmission. Arch Intern Med 152 (1992) 125-130
53. Owen W.F., Lew N.L., Liu Y., et al. The urea reduction ratio and serum-albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329 (1993) 1001-1006
54. Fleck A., Hawker F., Wallace P.I., et al. Increased vascular-permeability-a major cause of hypoalbuminemia in disease and injury. Lancet 1 (1985) 781-784
55. Ballmer P.E., Ballmerhofer K., Repond F., et al. Acute suppression of albumin synthesis in systemic inflammatory disease-an individually graded response of rat hepatocytes. J Histochem Cytochem 40 (1992) 201-206
56. Sreedhara R., Avram M.M., Blanco M., et al. Prealbumin is the best nutritional predictor of survival in hemodialysis and peritoneal dialysis. Am J Kidney Dis 28 (1996) 937-942
57. Dumler F. Use of bioelectric impedance analysis and dual-energy x-ray absorptiometry for monitoring the nutrition status of dialysis patients. ASAIO J 43 (1997) 256-260
58. Davies S.J., Phillips L., Griffiths A.M., et al. Analysis of the effects of increasing delivered dialysis treatment to malnourished peritoneal dialysis patients. Kidney Int 57 (2000) 1743-1754
59. Hakim R.M., and Lazarus J.M. Initiation of dialysis. J Am Soc Nephrol 6 (1995) 1319-1328
60. Eustace J.A., Coresh J., Kutchey C., et al. Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia. Kidney Int 57 (2000) 2527-2538
61. Caglar K., Fedje L., Dimmitt R., et al. Therapeutic effects of oral nutritional supplementation during hemodialysis. Kidney Int 62 (2002) 1054-1059